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Abstract
We present the first demonstration of glycated albumin detection and quantification using Raman spectroscopy without
the addition of reagents. Glycated albumin is an important marker for monitoring the long-term glycemic history of
diabetics, especially as its concentrations, in contrast to glycated hemoglobin levels, are unaffected by changes in
erythrocyte life times. Clinically, glycated albumin concentrations show a strong correlation with the development of serious
diabetes complications including nephropathy and retinopathy. In this article, we propose and evaluate the efficacy of
Raman spectroscopy for determination of this important analyte. By utilizing the pre-concentration obtained through drop-
coating deposition, we show that glycation of albumin leads to subtle, but consistent, changes in vibrational features, which
with the help of multivariate classification techniques can be used to discriminate glycated albumin from the unglycated
variant with 100% accuracy. Moreover, we demonstrate that the calibration model developed on the glycated albumin
spectral dataset shows high predictive power, even at substantially lower concentrations than those typically encountered
in clinical practice. In fact, the limit of detection for glycated albumin measurements is calculated to be approximately four
times lower than its minimum physiological concentration. Importantly, in relation to the existing detection methods for
glycated albumin, the proposed method is also completely reagent-free, requires barely any sample preparation and has
the potential for simultaneous determination of glycated hemoglobin levels as well. Given these key advantages, we believe
that the proposed approach can provide a uniquely powerful tool for quantification of glycation status of proteins in
biopharmaceutical development as well as for glycemic marker determination in routine clinical diagnostics in the future.
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Introduction
Glucose forms the most ubiquitous energy source in biology. In
humans, glucose is primarily derived from the breakdown of
carbohydrates in the diet or in body stores (glycogen), in addition
to secondary endogenous synthesis from protein or from the
glycerol moiety of triglycerides [1]. Importantly, even under
diverse conditions (such as feeding, fasting and severe exercise), the
blood glucose level is maintained within a fairly narrow interval,
70–120 mg/dL, by the homeostatic system of a healthy individual.
This implies that, for an average person, the total quantity of
glucose in the blood and body fluids is approximately 5 grams - a
remarkably small number given the typical carbohydrate intake
per day (ca. 150–200 grams). To maintain this natural balance, an
intricate set of biomolecule interactions, modulated by glucor-
egulatory hormones such as insulin, needs to occur. However, in
people afflicted with diabetes mellitus, the defective nature of
carbohydrate metabolism (stemming from inadequate insulin
production, response or both) leads to the presence of high blood
glucose. Ominously, diabetes, which affects more than 25 million
people in the US alone [2], has no established cure. As a
consequence, early diagnosis and careful management of diabetes
via frequent monitoring of glucose level is imperative in alleviating
the severe associated health complications including micro- and
macro-vascular diseases [3]. Presently, diagnosis and therapeutic
monitoring of diabetes requires direct measurement of glucose by
withdrawal of blood or/and interstitial fluid, both for clinical
laboratory measurements as well as for self-monitoring of blood
glucose. In order to reduce/eliminate the painful and invasive
nature of these fingerprick measurements, minimally invasive [4–
7] and non-invasive glucose monitoring has been actively pursued
by a number of research laboratories [8–10] including our own
[11–14].
In addition to these ‘‘gold standard’’ blood glucose measure-
ments, measurement of glycated proteins has received consider-
able contemporary attention in the medical community for
monitoring long-term glycemic control in diabetics [15,16].
Specifically, glycated hemoglobin (HbA1c) and glycated albumin,
which are formed by the non-enzymatic attachment of glucose to
hemoglobin and serum albumin respectively, have been proposed
as retrospective indices of the integrated blood glucose values over
extended periods of time [17–20]. Importantly, these markers are
not subject to the substantive variations observed in blood glucose
concentration measurements, due to their intrinsic half-lives of 120
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days (HbA1c) and 21 days (glycated albumin). While HbA1c
measurements have been more extensively employed in clinical
laboratories as an adjunct to blood glucose determinations, studies
over the past decade have suggested that glycated albumin
remains an ‘‘underestimated marker of diabetes’’ [21] and is, in
fact, ‘‘a better indicator for glucose excursion than glycated
hemoglobin in type 1 and type 2 diabetes’’ [22]. Notably, HbA1c
values are significantly affected by shortening of erythrocyte life
span [23–26] and are also prone to inaccuracies in the case of
several chronic diabetes-related disorders (e.g. hemolytic or renal
anemia and liver cirrhosis) [27–29]. On the other hand, glycated
albumin is more sensitive to shorter term alterations in blood
glucose values (due to its shorter half-life) and is not affected by
changes in erythrocyte survival times nor by abnormal hemoglobin
metabolism observed in some type 2 diabetes cases [28,29]. From
a clinical perspective, the value of glycated albumin determination
has been further highlighted by reports of the strong correlation
between glycated albumin concentrations and the development of
serious diabetes complications including nephropathy [30],
retinopathy [31] and arterial stiffening [32]. In light of these
reports, one can reasonably infer that measurement of glycated
albumin provides a crucial piece of information to complement
plasma glucose and HbA1c determination for appropriate diabetes
monitoring and therapeutics.
Current methods of glycated albumin determination include
affinity chromatography, high-performance liquid chromatogra-
phy and specific reagent-based colorimetric methods (e.g. thiobar-
bituric acid assay and nitro-blue tetrazolium assay). Nevertheless,
as detailed by Sacks [33], these methods are not widely used
because of their lack of suitability for routine clinical laboratory
application. For example, the aforementioned colorimetric assays
suffer from lack of specificity [34] and are vulnerable to the
presence of free glucose, uric acid or lipemia [35–37]. Further-
more, the development of monoclonal antibodies specific to
glycated albumin [38], while beneficial in principle, has not caused
a rise in the availability of commercial glycated albumin assays at
this present time.
In this context, optical/spectroscopic approaches provide a
reagent-free detection method, which can be performed with little
or no sample preparation. Previously, fluorescence spectroscopy
has been employed to differentiate between glycated and
unglycated albumin [39] as well as to characterize the effect of
anti-oxidants on glycation-induced changes in proteins [40].
Nevertheless, to overcome the lack of specificity of intrinsic
fluorescence spectroscopy (i.e. without addition of external dyes),
investigators have used FTIR (Fourier-transform infrared) spec-
troscopy. FTIR spectroscopy is sensitive to changes in secondary
structure and has provided valuable information on dynamic
build-up of glycated albumin when incubating albumin with
glucose [41,42]. Alternately, one can obtain (complementary)
vibrational information by using Raman spectroscopy. Notably,
Raman can be used to analyze aqueous solutions as it does not
suffer from the large water absorption effects associated with FTIR
and, generally, provides higher spectral detail (due to less
cluttering of peaks).
In this article, we propose a new Raman spectroscopy-based
method for selective and sensitive determination of glycated
albumin. Specifically, a derivative of spontaneous Raman
spectroscopy, known as drop coating deposition Raman (DCDR)
spectroscopy [43], is employed here to investigate the feasibility of
reproducible identification and accurate quantitation of this
important glycemic marker. In addition to the well-characterized
advantages of Raman spectroscopy (such as excellent chemical
specificity which obviates the need for exogenous reagents [44]),
this technique provides signal amplification by pre-concentration
of the analytes in solution. This pre-concentration – which is
obtained by the simple drying of a droplet of the analyte solution
(i.e. the so-called ‘‘coffee-ring effect’’, stemming from the interplay
of contact line pinning, solvent evaporation and capillary flow
[45]) – enables the Raman measurement of analytes at 2–3 orders
of magnitude lower than otherwise possible, without sacrificing
their solution conformation [46–48].
Herein, our DCDR measurements reveal that glycation of
albumin manifests itself in subtle but consistent changes in
spectral features. In fact, in combination with standard
multivariate chemometric methods, we observe that the glycated
albumin can be discriminated from the unglycated samples with
100% accuracy. Moreover, we characterize the accuracy and
precision of these measurements and demonstrate that the
developed calibration models show high predictive power, even
at substantially lower concentrations than typical physiological
levels. Finally, we establish the limit of detection of this method
for glycated albumin measurements. Based on the results
obtained here, the proposed approach can be expeditiously
employed for characterization of glycation status of proteins in
mixtures, which is of critical importance because glycation can
modify the stability, pharmacokinetics and immunogenicity of
glycoprotein-based biopharmaceuticals. Additionally, Raman
spectroscopy-based inspection of glycated albumin as a comple-
mentary glycemic marker exhibits substantive promise for similar
determination in serum and whole blood samples. We envision
that, in the future, this method will be enable us to provide real-
time, reagent-free and simultaneous measurement of both
glycated albumin and HbA1c providing a uniquely powerful tool
for clinical laboratories.
Materials and Methods
Our aim in this study is to develop DCDR as a complementary
tool for qualitative and quantitative investigation of glycated
albumin. As alluded to above, in this technique, spectroscopic
measurements are performed on the coffee-ring pattern, where the
analytes (e.g. proteins) are deposited from the drying drop. Herein,
systematic experimental studies were initiated to achieve a two-
fold objective. First, we assess the ability of the proposed approach,
in conjunction with multivariate chemometric methods, to clearly
distinguish pure albumin and glycated albumin samples. Second,
we evaluate the quantitative ability of this method to precisely and
accurately predict the concentration of glycated albumin at
physiologically relevant levels and below. For the purpose of
achieving these objectives, Raman spectroscopic measurements
were performed on multiple drop-coated samples derived from a
wide range of albumin and glycated albumin solutions, respec-
tively. The acquired spectra were first examined for specific
Raman bands and, subsequently, to discriminate between the
samples. Subsequently, basic regression methodology was em-
ployed to quantitatively predict glycated albumin concentrations
from the Raman spectroscopic measurements obtained from drop-
coated depositions and to establish the prediction accuracy,
precision and limit of detection of the proposed approach. In
addition to the spectroscopic measurements, we also performed
2D spatial Raman mapping on representative drop-coated
samples to investigate the uniformity (or the lack thereof) of the
distribution of the analytes of interest (namely, albumin and
glycated albumin). Evidently, the lack of substantial variance in
measurements performed at a constant radial distance would
manifest in higher reproducibility of the predicted concentrations
from the drop-coated depositions.
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Experimental
For this study, a home-built Raman spectroscopic system
equipped with a 785 nm CW Ti:Sapphire laser (3900S, Spectra-
Physics), which was pumped using a frequency-doubled Nd:YAG
laser (Millennia 5sJ, Spectra-Physics), was used. A liquid-nitrogen
cooled CCD (LN/CCD 1340/400-EB, Roper Scientific) com-
bined with a spectrograph (Kaiser Holospec f/1.8i) was used for
collection of the spectra. A water immersion objective lens
(Olympus UPLSAPO60XWIR 60X/1.20) focuses the laser to a
spot size of approximately 1 mm on the sample and collects the
backscattered Raman light. Due to the non-absorptive nature of
the albumin and glycated albumin deposits, the power at the
sample could be kept relatively high at ca. 30 mW without the
possibility of optical and/or thermal damage to the samples. The
detailed description of this system can be found in one of our
laboratory’s previous publications [49]. It should be noted that
while this laboratory system was used in our experiments for the
sake of convenience, a considerably simpler system comprising a
single frequency diode laser would be adequate for these
investigations.
Lyophilized powder samples of human serum albumin and
glycated albumin were obtained from Sigma-Aldrich (St. Louis,
MO, USA). The aqueous solutions of albumin were prepared in
the range of 23–750 mM (the typical physiological range is
between 3.5–5.5 g/dL or, ca. 510–710 mM [50]). Corresponding-
ly, glycated albumin samples were formulated with concentrations
in the range of 7–250 mM (typical physiological values are 10–25%
of the above mentioned albumin concentrations [51]). All sample
preparations are performed using high purity PESTANAL water
(Fluka) to ensure the reproducibility of the measurements. Drop-
coated depositions were prepared by pipetting aliquots (4 mL) of
the prepared solutions on quartz coverslips (which were used to
avoid the strong fluorescence interference of glass) and air-drying
for approximately 20 minutes. The air-dried annular rings had
widths in the range of 40–700 mm and scaled roughly in a linear
fashion with respect to the concentrations (consequently, the
albumin samples had larger annular ring widths in comparison to
the glycated albumins samples). Figure 1 shows (portions of the)
annular rings obtained from the glycated albumin samples after
solvent evaporation, where (a) has the highest analyte concentra-
tion and (f) the lowest.
The acquisition time for all the Raman spectra was 10 seconds.
For the classification and regression studies, spectra were collected
from each sample at three different points at a constant radial
distance from the center, with five replicate measurements at each
location. The spectroscopic measurements were performed on the
approximate center of the annular region (e.g. the position between
the two concentric arcs marked by the asterisk in Fig. 1(a)) where
the analytes accumulate due to solvent evaporation. It should be
noted that this is different from the center of the entire ring, where
little or no analyte deposition takes place (as confirmed by the lack
of analyte-specific Raman spectral features in this region). Further
mention of the drop-coated deposit should be taken as referring to
the former, i.e. the analyte-rich annular region, unless otherwise
noted. In addition for the investigation of the uniformity, 100
spectra were collected over a 80680 mm field of view with 8 mm
inter-point distance (2D spatial Raman mapping). The spectra
acquired from these studies were subject to vertical binning and
cosmic ray removal. No background correction was performed for
the ensuing quantitative analysis due to the possibility of
incorporation of spurious artifacts [52].
Data Analysis
In order to investigate the classification ability of the proposed
method between albumin and glycated albumin samples, we
performed principal component analysis (PCA) (part of the
Figure 1. Bright field images of the drop-coated deposition rings. Bright field images of the drop-coated deposition rings obtained from air-
drying of aq. glycated albumin samples. Evidently, the analytes are concentrated in the annular ring. The samples (a)–(f) are arranged in the order of
descending concentration levels of glycated albumin, which is reflected in the widths of the corresponding rings. The asterisk in Fig. 1(a) represents
the approximate center of the annular analyte-rich region. In all drop-coated deposition rings, spectroscopic measurements were performed at this
approximate center location, where the Raman signal intensity was maximum.
doi:10.1371/journal.pone.0032406.g001
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Statistics Toolbox in MATLAB R2010b (MathWorks, Natick,
MA)) on the entire dataset containing 180 spectra in all. In
particular, 90 spectra were acquired from 6 concentrations of
albumin and, similarly, 90 more spectra were collected from 6
glycated albumin concentrations (where the concentrations of each
analyte were in the ranges mentioned previously). Principal
component analysis (PCA) is a dimension reduction technique,
which uses an orthogonal transformation to convert a set of
observations of closely correlated variables into a set of values of
uncorrelated variables called principal components (PC). The first
few principal components (each PC is orthogonal to the preceding
one) account for a high degree of the net variance and are often
used for visualizing the primary differences between the classes
[53,54]. Here, logistic regression on the relevant principal
components was pursued to obtain a separation plane between
the samples and to ascertain the degree of classification accuracy.
Logistic regression is a standard discriminate analysis technique,
which is employed here to correlate the principal component
scores with the sample classes (namely, albumin and glycated
albumin) [55,56].
Moreover, in order to illustrate the capability of DCDR to
provide quantitative measurements of these analytes, partial least
squares (PLS) regression was employed [57]. Specifically to gauge
the reproducibility of the measurements in the 2D spatial Raman
mapping study, a leave-one-sample-out PLS model (developed on
the 75 spectra from 5 calibration samples) was used to predict the
concentrations for the 100 prospective spectra collected over a 2D
area of the ring on a representative glycated albumin sample.
For the quantification of the accuracy and precision of our
measurements, we have performed leave-one-sample-out cross-
validation procedure on the glycated albumin data acquired from
the 6 samples. In the leave-one-sample-out cross-validation
routine, one sample is left out when developing the calibration
model and the resultant model is used to predict concentrations of
the left out sample spectra. This procedure is repeated until all
samples are left out and all concentrations are predicted. In
particular, the calibration models are developed using 75 spectra
(5 samples with 15 spectra per sample) and the predictions are
performed on the remaining 15 spectra (1 sample) to obtain 15
predicted concentrations. This routine is repeated till all the
glycated albumin samples (and spectra therein) are accounted for.
Here, three figures of merit, namely relative error of prediction
(REP), relative standard deviation (RSD) and limit of detection
(LOD), were computed. The REP and RSD values correlate
directly with the accuracy and precision of DCDR predictions,
respectively. In the following, we provide the equations used for
computing the figures of merit:
(i) Average relative error of prediction, REP:
REP (%)~
100
N
XN
i~1
c^i{ci
ci

 ð1Þ
where N is the number of spectra in the dataset, ci is the
reference concentration and cˆi is the predicted concentra-
tion.
(ii) Average relative standard deviation of predicted concentra-
tions, RSD:
RSD (%)~
100
Nconc
XNconc
k~1
sck
ck
where s2ck
~
Xp
i~1
c^ik{ckð Þ2
p{1
ð2Þ
where Nconc is the number of distinct concentrations in the
dataset, p is the number of spectra per concentration and sck
is the standard deviation obtained at concentration ck.
(iii) Limit of detection (LOD), as per the IUPAC definition [58],
is computed from the best fit line obtained between
predicted concentrations and reference concentrations [59]:
LOD mMð Þ~3 sy=x
slope
where sy=x~
X
i
(c^i{ci)
2
N{2
2
64
3
75
1=2
ð3Þ
where sy/x is the standard deviation of the residuals and is a
measure of the average deviation of the predicted values
from the regression line.
Results and Discussion
Figure 2 shows Raman spectra acquired from typical drop-
coated depositions of human serum albumin (green) and glycated
albumin (red) solutions. For the sake of visual representation, the
plots shown in Fig. 2 were subject to 5 spectra averaging from each
sample and baseline-removal [60]. (It is worth emphasizing that
the baseline-removed spectra were not used for any of the
following analysis, as mentioned in Materials and Methods
section.) The features observed in our (DCDR) albumin spectrum
are consistent with those previously reported in the literature for
albumin solutions [61–63]. A summary of the wavenumbers and
their corresponding tentative Raman band assignments is given in
Table 1. In particular, we note the presence of the following key
features: 1655 cm21 Amide-I band, 1447 cm21 CH2 deformation
band, 1002 cm21 phenylalanine band and the tyrosine doublet at
828 and 850 cm21. The Amide-I band is a characteristic feature
of the a-helical (secondary) conformation of the polypeptide
backbone stemming mainly from peptide C=O stretching
vibration [64]. This is important because any change of this band
would indicate a modification in the secondary structure of human
serum albumin, which is predominantly an alpha-helical molecule
(67%). Furthermore, the strong phenylalanine peak at 1002 cm21
is reflective of the presence of 31 phenylalanine residues present in
albumin (tryptophan may provide a small contribution to the
intensity of the 1002 cm21 band as well).
Expectedly, the glycated albumin spectrum does not exhibit any
gross differences in comparison to the albumin spectrum (although
subtle changes in the Raman spectra in the 780–850 cm21 region
exist). Numerous studies have previously identified that (non-
enzymatic) glycation of albumin occurs at multiple sites corre-
sponding to the arginine, lysine and cysteine residues, which can
be attributed to their high nucleophile properties [21,65–67].
Since the Raman signature of albumin do not have significant
contributions from these residues, one would anticipate that the
corresponding glycation-induced changes would be subtle. Nev-
ertheless, we hypothesize that these changes, although relatively
small, are consistent and, as such, provide sufficient information to
distinguish between albumin and glycated albumin samples.
Specifically, such small changes are routinely detected using
multivariate chemometric algorithms, which we have employed in
the following analysis to test this hypothesis. It is also worth
mentioning that glycation studies have indicated the conversion of
albumin into a high b-sheet structure [68,69] - another potential
marker that may aid the classification of glycated and unglycated
samples.
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To this end, PCA was employed to visualize the underlying
information from the multivariate spectral dataset, comprising
both albumin and glycated albumin samples (90 spectra from 6
samples at different concentrations for each of the analytes).
Figure 3(A) gives the first four principal components (which
together account for 99.74% of the net variance). We observe that
PC1 bears a striking resemblance to the pure albumin spectrum
(and by extension to the glycated albumin spectrum, albeit to a
somewhat lesser extent - especially in the 780–850 cm21 region).
PC2 retains some of the key features seen in PC1, although in
different proportions. Interestingly, a new feature is observed at ca.
792 cm21, which seems to stem from the differences in the
aforementioned shoulder region in the tyrosine doublet between
the glycated and unglycated samples. This feature is also present in
a prominent manner in PC 3 and 4. In addition, these PCs have
an interesting feature at ca. 1542 cm21, which was not noted in the
list of prominent bands in Table 1 and the origin of which is
unclear at this present time.
The corresponding scores plot for PCs 2, 3 and 4 is given in
Figure 3(B). (PC1 was excluded from this 3D plot because of its
relatively lower discriminative power between the two sets of
samples in comparison to the PCs employed here.) Remarkably,
we can see a clear separation between the albumin and glycated
albumin samples. To measure the discrimination ability of the
proposed approach, we used logistic regression on the scores of PC
2, 3 and 4 (i.e. score2, score3 and score4, respectively). The optimal
separation plane, based on these three parameters, was computed
to be:
3:9225{0:0027 score2z0:0023 score3z0:0041 score4~0 ð4Þ
This logistic regression algorithm gave a classification accuracy of
100%, as can be seen from Fig. 3(B). To test whether such a
classification result could have been obtained from spurious
correlations (such as system drift during measurements), we
performed two control studies. First, we assigned the ‘‘albumin’’
and ‘‘glycated albumin’’ labels randomly to the 180 spectra,
without any regard for their actual origin. We observed that the
new ‘‘optimal’’ logistic regression algorithm barely gave 55%
classification accuracy (which in this binary classification problem
is akin to a random guess). This underlines the inability of the
algorithm to predict the randomly assigned classes. Subsequently,
we assigned class labels in correlation with the measurement order
of the samples to investigate the possibility of temporal correlations
(e.g. that stemming from system drift). In other words, we assigned
the first 90 samples as albumin and the last 90 as glycated albumin
(whereas the spectral measurements were performed in an
arbitrary manner between the albumin and glycated albumin
samples). Here, too, the ‘‘optimal’’ logistic regression algorithm
displayed poor performance, and the overall classification
accuracy was computed to be ca. 60%. Taken together, the actual
logistic regression performance and the control studies validate our
hypothesis that the chemometric methods can reliably predict class
labels based on subtle, but consistent, differences in spectral
features between albumin and glycated albumin samples. The
control studies, in particular, also underline the robustness of
DCDR in combination with multivariate classification to chance
correlations.
Since PCA and logistic regression showed excellent discrimina-
tion ability from the DCDR spectra, we used a multivariate
regression approach (PLS) to test the predictive power of the
glycated albumin data. Before this test, however, it is important to
Figure 2. Raman spectra acquired from the drop-coated
albumin and glycated albumin samples. Raman spectra acquired
from the drop-coated albumin and glycated albumin samples derived
from their corresponding aqueous solutions, respectively (the spectra
are normalized and offset for the sake of clarity). The asterisks indicate
the principal peaks, namely the 1655 cm21 Amide-I band, the
1447 cm21 CH2 deformation band, the 1002 cm
21 phenylalanine band
and the tyrosine doublet at 828 and 850 cm21.
doi:10.1371/journal.pone.0032406.g002
Table 1. Chemical assignments of vibrational modes for the
Raman spectra acquired from drop-coated deposition of
human serum albumin sample.
Wavenumber (cm21) Tentative Band Assignments
1655 Amide-I
1616 Tyr
1605 Phe
1584 Phe
1447 d(CH2)
1335 d(CH)
1319 d(CH)
1208 Tyr+Phe
1172 Tyr
1157 u(CN)
1125 u(CN)
1102 u(CN)
1089 u(CN)
1031 Phe
1002 Phe
960 u(CC)
940 u(CCN)sym, u(CC)
899 u(CC)
850 Tyr
828 Tyr
667 u(CS)
643 Tyr
Here, n means stretching vibration; and d deformation. Tyr, Trp and Phe refer to
the tyrosine, tryptophan and phenylalanine residues, respectively.
doi:10.1371/journal.pone.0032406.t001
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Figure 3. PCA decomposition of the spectral dataset. (A) The first four principal components corresponding to the entire spectral dataset
acquired from the albumin and glycated albumin drop-coated deposition samples. These four principal components, combined, explain 99.74% of
the net variance in the dataset. (B) Scores plot corresponding to principal components 2, 3 and 4 for the spectral dataset acquired from albumin and
glycated albumin drop-coated rings. The albumin and glycated albumin samples are indicated by green circles and red squares, respectively. The
optimal plane of separation, shown here, is constructed using a logistic regression algorithm (further details are noted in the text).
doi:10.1371/journal.pone.0032406.g003
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characterize the reproducibility of the measurements by comput-
ing the potential variations in the radial and, more importantly, in
the angular direction. Here, we have performed 2D spatial Raman
mapping-based predictions on a representative glycated albumin
sample (reference analyte concentration = 31.25 mM) using PLS
calibration models developed on the other 5 sample spectra.
Figure 4 plots the results of this analysis for the 100 spectra
acquired over a 80680 mm area of the annular ring. The profile
along the radial direction (X-axis) shows an approximately
symmetric shape with a steeper descending outer part (i.e. over
pixels 8, 9 and 10) in comparison to the more gradual descent in
the inner part of the ring (i.e. over pixels 3, 2 and 1). This is
consistent with previous experimental observations of complete
desiccation at the outer perimeter of the ring, primarily from
oscillation of the droplet contact line [70–72]. On the other hand,
there is a high degree of consistency between the predictions along
the Y-axis, which for small distances (such as those considered
here) provides a reasonable approximation for the angular
direction. The coefficient of variation (i.e. the ratio of standard
deviation to the mean of the predicted concentrations) along the
Y-axis is calculated to be in the range of 0.014–0.074 with a mean
of 0.038. This demonstrates the excellent reproducibility of the
spectral predictions along the analyte-rich annular region of the
ring, when the measurements are performed at a constant radial
distance. Importantly, we also observe that the reference values of
the glycated albumin concentrations are reproduced fairly
accurately near the centre portion of the ring, i.e. the average of
the predicted concentration over pixels 5 and 6 on the X-axis is
29.9 mM. Clearly, the absence of significant inhomogeneity in the
drop-coated samples substantially increases the enthusiasm for
systematic assessment of the prediction accuracy and precision
across a wide range of concentrations.
Figure 5 shows the results of leave-one-sample-out cross-
validation for the glycated albumin samples, where the reference
and PLS predicted concentrations are given along the X- and Y-
axis, respectively. The solid black line illustrates y = x and is given
to explicitly understand the linearity of the response (or the lack
thereof). From the figure, it is evident that the predicted values
show excellent agreement with the reference concentrations and
the corresponding correlation coefficient between these two set of
values is calculated to be 0.9986. Further, the relative error of
prediction (REP) was calculated to be ca. 16%, showing thereby
that PLS provides very accurate predictions for the DCDR
glycated albumin data over the entire concentration range of 7–
250 mM. When the glycated albumin sample having 7 mM
concentration is omitted from the dataset (as it is below the limit
Figure 4. 2D spatial Raman mapping of a glycated albumin drop-coated ring. 2D spatial Raman mapping based concentration prediction
results for a representative glycated albumin drop-coated ring. The reference glycated albumin concentration in this sample is 31.25 mM. The field of
view is 80680 mm with a pixel-to-pixel distance of 8 mm. Here, the X- and Y-axis provide a close approximation to the radial and angular directions,
respectively. Pixel 1 on the X-axis is located closer to the center of the ring (inner periphery) and pixel 10 is farthest away from the ring center.
doi:10.1371/journal.pone.0032406.g004
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of detection of our system as discussed below), the REP value
drops to 8.5%.
Finally, we evaluated the precision of our measurements using
the relative standard deviation (RSD) metric. For the entire
concentration range, our precision was observed to be 21.6%.
Notably, when the 7 mM glycated albumin sample was not
included in this analysis, the RSD metric reached a clinically
acceptable value of 11.6%. Naturally, the precision gets worse as
the concentration of the analyte decreases - a common
characteristic of any spectrochemistry measurement. This aspect
is revealed in Fig. 6 (also known as a precision profile in clinical
chemistry), where the RSD is graphically plotted as a function of
the reference glycated albumin concentration.
At this point, we determined the limit of detection (LOD) using
the standard deviation of the residuals and the slope of the
regression line, the so-called calibration plot method. Here, our
LOD for glycated albumin was computed to be 13.7 mM, which is
evidently higher than the lowest concentration used in this study
(7 mM) but lower than the remaining sample concentrations. More
importantly, this value is nearly 4 times less than the lowest
physiological concentrations likely to be encountered in clinical
settings (ca. 50 mM). Quantitatively speaking, the RSD is also 33%
at the limit of detection (as per the IUPAC definition or 3s
detection limits) and therefore one can graphically extrapolate the
RSD versus concentration plot to arrive at the LOD. Here, using
this alternate method, we found the LOD value to be 14.7 mM.
The small deviation from the previous value (13.7 mM) can be
attributed to the deviation from an ideal exponential fit seen in
Fig. 6. Nevertheless, it is reassuring that both methods generate
very close numbers strengthening our confidence in the system’s
capability of measuring very low concentrations of glycated
albumin.
In summary, a novel analytical procedure for reproducible
identification and accurate quantification of glycated albumin has
been proposed in this article. This method can also provide a real-
time, reagent-free and largely non-perturbative alternative for
probing glycation status of similar proteins in mixture solutions,
which can aid in glycoprotein-based biopharmaceutical research and
development. Moreover, while the experiments performed here
establish the proof-of-principle for glycated albumin detection on the
laboratory bench, further studies are currently underway to translate
it to clinical settings. These studies involve the measurements on
standard serum samples obtained from diabetic patients as well as
normal human subjects (at the Beth Israel Deaconess Medical
Center). Specifically, the samples are drawn by standard venipunc-
ture into ‘‘serum separator’’ tubes, which contain a compound that
speeds clotting and that, upon centrifugation, separates the serum
from the cellular components of the blood (red blood cells, white
blood cells, and platelets). Subsequently, drop coated plates are
prepared (as in the aforementioned proof-of-concept studies) to test
the efficacy of DCDR for glycated albumin determination in more
physiologically relevant serum samples. (The results of this clinical
study will be published in a follow-up article elsewhere.)
It is worth mentioning that in serum samples, the specificity (and
the precision) of this method is unlikely to be significantly
hampered due to two primary reasons. First, the concentrations
of all other analytes (biomolecules) in serum are substantially lower
in relation to physiological albumin concentration. In particular,
albumin has a reference concentration range of 35–52 g/L,
whereas the next highest concentration ranges belong to
immunoglobulin G (7–16 g/L) and transferrin (2–3.6 g/L) (with
almost all other serum constituents having concentrations less than
1 g/L [73]). Second, the strong and distinct Raman signal of
albumin (and its glycated counterpart) does not show substantive
Figure 5. PLS prediction results of glycated albumin samples. Prediction results obtained using partial least squares (PLS) regression on
glycated albumin samples. The solid line denotes y = x values.
doi:10.1371/journal.pone.0032406.g005
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spectral overlap with these major serum constituents [74,75].
Finally, significant improvements to the current results can be
made, especially through optimization of instrumentation and via
enhanced chemometric modeling.
Conclusions
This proof-of-concept study represents the first use of Raman
spectroscopy, without application of extraneous reagents, to detect
and quantify the concentration of glycated albumin, an important
glycemic marker for long-term diabetes monitoring. Specifically, we
have demonstrated that application of drop-coating deposition
Raman spectroscopy can accurately discriminate glycated albumin
from the unglycated variant, even at low mM concentrations.
Further, in conjunction with standard multivariate analysis
methods, we have shown that the limit of detection of the proposed
approach for glycated albumin is nearly 4 times lower than the
minimum physiological concentrations encountered in practice.
The proposed method provides a promising alternative for glycated
albumin determination as it is completely reagent-free and requires
barely any sample preparation. The next step in translating this
promising technology is to assess its predictive diagnostic value in
multi-component mixtures, especially in serum samples. Addition-
ally, in combination with recent studies of Raman-based charac-
terization of protein glycosylation status [76], our investigations
should advance the use of Raman and other spectroscopic
modalities (such as fluorescence, FTIR and 2D-IR absorption
spectroscopy [77]) for understanding the detailed structure and
dynamics of albumin transformation caused by different analytes of
interest, such as glucose and heavy metal ions [78].
Concomitantly, our laboratory is also engaged in investigating
the clinical feasibility of HbA1c determination using DCDR. The
combined determination of HbA1c and glycated albumin will
provide a uniquely powerful metric in estimating the ‘‘true’’
glycemic history of a patient - a feature that is currently lacking in
almost all clinical laboratories globally. The differences in the
lifetime of these two important glycemic markers should shed
interesting insight on the long-term glucose profile of a diabetic.
Furthermore, the measurement of two markers may be
imperative in certain clinical cases where one or the other may
provide inaccurate estimates. For example, HbA1c values have
been reported to underestimate the blood glucose levels in
patients with hemolytic anemia [27], or those submitted to
hemodialysis [79], whereas glycated albumin may not be an
appropriate indicator for glucose excursion in pathologies that
impact albumin metabolism, e.g. thyroid dysfunction and
nephrotic syndrome [80,81]. As a consequence, there is a
significant clinical need for rapid and reliable glycemic history
assessment that is (more) robust to other pathological changes.
We believe this clinical need can be bridged by appropriate
utilization of the proposed spectroscopic approach.
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